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Over the last decade a large body of epidemiological, translational, and animal
model research has suggested that psoriasis may be a risk factor for
cardiovascular and metabolic disease. Outcome based studies often suggest
that patients with more severe psoriasis have an increased risk of major
cardiovascular events independent of traditional risk factors that are captured in
electronic health data. The study by Parisi and colleagues ﬁnds that incident
severe psoriasis is associated with a non-statistically signiﬁcant increased risk of
major cardiovascular events, HR 1.28 (95% CI 0.96–1.69) in their primary model
and a statistically signiﬁcant increased risk, HR 1.46 (95% CI 1.11, 1.92), in a
sensitivity analysis that excludes patients with inﬂammatory arthritis. These
results are usefully consistent with prior studies published using the same or
similar databases. Here we review three key biostatistical and epidemiological
principles that are commonly misunderstood (over reliance on P-values,
confounding versus effect modiﬁcation, and inception versus prevalent cohort
design) and often lead to controversy in analyzing and interpreting results.
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Parisi et al. (2015) conducted an elegant
series of analyses of patients with
incident psoriasis using a population-
based data source (the Clinical Practice
Research Datalink) that has previously
been shown to be scientiﬁcally
valid for epidemiological studies, and
they conclude that neither psoriasis nor
severe psoriasis is associated with a risk
of major CV events after adjusting for
known CV disease risk factors. Using
the same inception cohort design and
the same database, Dregan et al. (2014),
writing in Circulation, reached the
opposite conclusion, ﬁnding that
psoriasis, in particular severe psoriasis,
is associated with an increased risk of
coronary heart disease independent of
traditional risk factors. Indeed, nearly a
decade earlier, using the same database
and a prevalent psoriasis design, we
found that psoriasis is associated with
an increased risk of myocardial infarc-
tion, stroke, and CV mortality indepen-
dent of traditional CV risk factors and
that the risk is most signiﬁcant in
patients with more severe psoriasis
(Gelfand et al, 2006,Gelfand et al,
2009,Mehta et al, 2010). So how do
sophisticated analyses using the same
data set yield such opposing conclu-
sions? In this commentary, we review
key biostatistical and epidemiological
principles that are commonly misunder-
stood and often lead to controversy in
analyzing and interpreting results. For a
discussion of statistical power, selection
bias, and information bias, the reader is
referred to our earlier editorials (Gelfand
et al., 2010; Gelfand et al., 2011).
Over-reliance on P-values
A common misinterpretation of inferen-
tial statistics for two-group compa-
risons is that a P-value 40.05 means
that there is no difference between the
groups. In the original discussion of the
P-value by Fisher (1926), the ﬁnding of
a P-value 40.05, particularly in the
setting of previous studies ﬁnding a
signiﬁcant difference, meant that the
experiment needed to be repeated, not
that no difference existed. As Dr Steven
Goodman, who has written extensively
on this topic, summarized nicely in his
paper, “Twelve P-value misconceptions,”
“The effect best supported by data from a
given experiment is always the observed
effect, regardless of its signiﬁcance.”
(Goodman, 2008). In other words, inter-
pretation of the point estimate of asso-
ciation takes precedence, followed by
an evaluation of the precision of this
estimate (e.g., a 95% conﬁdence interval
(CI)). Indeed, Parisi et al. (2015) report
that the point estimate of the risk of major
adverse cardiac events (MACE) in
patients with severe psoriasis is 1.28;
this exceeds the risk they estimate in
patients with diabetes (point estimate
1.18), which is widely accepted as a
major CV risk factor. The estimate by
Parisi et al. (2015) was not very precise
(95% CI 0.961.69), however, and thus
the P-value was 0.089. Using Fisher’s
development of the P-value concept, the
appropriate interpretation is that the
probability of Parisi et al. (2015) obser-
ving a hazard ratio (HR) of ⩾1.28 is
8.9%; this is then arbitrarily determined
to be not statistically signiﬁcant based on
standards developed in the agricultural
sciences (Fisher, 1926). Indeed, Dregan
et al. (2014), using the same database
and inception cohort design, found
nearly identical results; their point esti-
mate of the HR of coronary heart disease
in severe psoriasis was 1.29 (95% CI
1.01–1.64). Their P-value was 0.042,
(which we provide solely because
readers love P-values; who said science
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is not romantic!) making the result
statistically signiﬁcant using the arbitrary
(although well-accepted) standard. The
larger point is that these two results are
usefully consistent and lead to the same
general conclusion: any controversy
arises only because the two P-values
ﬁnd themselves on opposite sides of the
artiﬁcial fence erected at the 0.05 level.
Confounding versus effect modiﬁcation
The relationship between psoriasis and
CV disease is complicated because they
share a number of common confound-
ing factors. A confounder is deﬁned as a
factor that is “associated with the expo-
sure and, independent of that exposure,
is a risk factor for the disease” (Hennekens
and Buring, 1987). Critically, a confound-
ing variable must be predictive of out-
come independent of its association with
the exposure variable. A classic example
of a confounding variable is smoking
status. Smoking is known to be associated
with psoriasis and, independent of its
association with psoriasis, is associated
with CV disease. Methods of accounting
for confounding in an epidemiologic
study include stratiﬁcation on that vari-
able (to examine the exposure–outcome
relationship at each level of the con-
founder rather than averaging over levels
of the confounder), matching on the con-
founder to balance the groups included
in the analysis, restricting the cohort to
a particular level of the confounder, or
adjusting for the confounder using a
multivariable model. When we adjust
for smoking in the model examining the
relationship of the exposure (psoriasis)
with the outcome (MACE), it means that
the ﬁnal estimate measures the relation-
ship between exposure and outcome
for any given level of the confounder
(smoker, nonsmoker, or past smoker).
An effect modiﬁer may also have a
signiﬁcant relationship with the exposure
and the outcome but differs from a
confounder in that it moderates the
relationship between exposure and out-
come. Effect modiﬁcation is deﬁned as “a
measure of exposure effect across levels of
another variable” (Greenland, Rothman
and Lash, 2008). Effect modiﬁcation is
often referred to as heterogeneity of effect
or statistical interaction. The key differ-
ence is that epidemiologists try to
eliminate confounding (through the
approaches described above) but want
to detect and describe effect measure
modiﬁcation (Greenland, Rothman and
Lash, 2008). There are several variables
from the statistical model reported by
Parisi et al. (2015) that are likely effect
modiﬁers and therefore should not be
adjusted for as confounding variables.
Psoriatic arthritis (PsA) is one example.
First, PsA seems unlikely to meet the
deﬁnition of a confounder as its associ-
ation with the outcome is unlikely to be
independent of its association with
cutaneous psoriasis: they are part of the
same clinical disease presentation. Thus,
instead of trying to eliminate the effect
of PsA through multivariable adjustment,
it would be more clinically and
scientiﬁcally appropriate to detect
and describe the effect of psoriasis and
psoriatic arthritis on CV risk. An intuitive
and simple approach is to use
stratiﬁcation. In Supplementary Table
S1 online, when Parisi removed all
patients with PsA (a form of stratiﬁcation)
we see that the fully adjusted HR of
severe psoriasis is 1.46 (95% CI 1.11–
1.92) (apologies to P-value enthusiasts
but no P-value was reported). This result
indicates that patients who have not
been diagnosed with psoriatic arthritis
but have psoriasis being treated with
systemic or phototherapy (i.e., severe
psoriasis) have a 46% increased risk
major CV events even when adjusting
for many common CV risk factors. It
would be helpful to clinicians and
patients if a similar estimate were
provided for severe PsA and mild skin
disease, but this is admittedly difﬁcult to
determine using the amount of informa-
tion provided in automated medical
record databases.
“Parisi's results are
consistent with previous
studies suggesting that
more severe psoriasis is
a risk factor for major
cardiovascular (CV)
events independent of
traditional risk factors
routinely assessed in
the clinical setting.”
Inception design versus prevalent cohort
design
In an incident disease cohort, disease
duration is assumed to be zero at
entrance into the cohort (although the
determination of when disease actually
begins is complex and the validity of
identifying truly incident psoriasis in
a medical records database has not been
shown). An incident disease cohort (also
known as an inception cohort) is the
preferred design for fully capturing risk
when disease-related outcomes occur
early. This type of design is especially
important for drug safety studies. How-
ever, in the setting of psoriasis and CV
risk, disease duration (and thus long-term
exposure to inﬂammation) is related to
the outcome, with increased risk of the
outcome as the duration increases. For
example, rheumatoid arthritis patients
with longer disease duration have a
higher risk of CV events than patients
with shorter disease duration (Masuda
et al, 2014). This issue has been similarly
demonstrated in patients with psoriasis
(Armstrong et al, 2012, Li et al, 2012).
Thus use of an inception cohort with
only short-term follow-up will result in
underestimation of the true effect; for this
reason, we have chosen to use prevalent
disease designs in our studies to better
represent psoriasis patients in the general
population. For example, the average
patient with psoriasis in the general
population has had it for two decades,
suggesting that an inception design
will not be generalizable to a large
percentage of patients. Prevalent
designs, however, may lead to under-
estimation of the effect through a phe-
nomenon known as deletion of
susceptibles if the outcome is related to
mortality (as in the case of MACE); a
prevalent cohort design has limitations
as well. Nevertheless, limiting the size of
the cohort through the use of the
incident disease design reduces the
generalizability of the ﬁndings and
results in lower power to detect a differ-
ence in the risk of outcomes between the
exposure groups and, subsequently,
leads to wider conﬁdence intervals.
In summary, Parisi et al. (2015)
addressed the risk of CV disease among
patients with psoriasis but arrived at a
different conclusion compared with other
studies performed using the same or
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similar databases. Important differences
in the study design, including the use
of disease severity and inﬂammatory
arthritis as confounders rather than
effect modiﬁers and the use of an inci-
dent disease cohort, likely explain the
small differences in the ﬁnal point
estimates. When excluding patients with
inﬂammatory arthritis, the results were
nearly identical to those reported in our
study using The Health Improvement
Network (a database similar to the
Clinical Practice Research Datalink;
Ogdie et al, 2015). An advantage of
both our study and that of Dregan et al.
(2014) is that they simultaneously asses-
sed the risk for CV disease in inﬂam-
matory arthritis (rheumatoid arthritis and
PsA); Dregan et al. (2014) also examined
Crohn’s disease and vasculitis. In both
of these studies, severe psoriasis carried
the same or higher risk than all of
these conditions. These simultaneous
comparisons aid in interpreting the
results, and they place the results into a
clinical context. Similar to patients with
rheumatoid arthritis and other systemic
inﬂammatory disorders, patients with
severe psoriasis have an elevated risk
of CV disease, one that appears to be
independent of common CV risk factors
recorded in the primary care setting.
Patients with psoriasis, in particular
severe psoriasis, should be screened
for traditional CV risk factors and these
risk factors should be managed appro-
priately (Takeshita et al., 2015). Because
psoriasis, even when severe, often
remains untreated, a critical question is
whether control of inﬂammation leads
to a decreased risk of major adverse
CV events. Observational data, largely in
rheumatoid arthritis and to a lesser
degree in psoriasis, indicate that tumor
necrosis factor inhibitors and metho-
trexate are associated with a reduction
in CV risk (Roubille et al., 2015). To
extend these results experimentally, we
are conducting the Vascular Inﬂamma-
tion in Psoriasis Trials (NCT01553058,
NCT02187172, NCT01866592); these
are randomized, placebo-controlled clin-
ical trials to determine the impact of
psoriasis treatments such as adalimumab,
ustekinumab, and phototherapy on key
pathways of CV disease, including aortic
inﬂammation measured by [18F]-ﬂuoro-
deoxyglucose positron emission tomo-
graphy–computed tomography (Mehta
et al., 2011; Mehta et al., 2012). Further-
more, Ridker and colleagues are con-
ducting a randomized clinical trial
investigating whether taking low-dose
methotrexate reduces heart attacks,
strokes, or death in people with type 2
diabetes or metabolic syndrome who
have had a heart attack or multiple
coronary blockages (NCT01594333)
(Ridker, 2010). Ultimately, these trials
will provide greater insight into the clini-
cal signiﬁcance and potentially causal
nature of psoriasis-associated CV risk.
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